Search Results

Notable Labs, Ltd. reported financial results for the year ended December 31, 2023 and provided a business update.

Notable Labs, Ltd. (“Notable”) (Nasdaq: NTBL), a clinical stage therapeutic platform company developing predictive precision medicines for cancer patients, today announced that Thomas Bock, M.D., CEO of Notable Labs, will participate in a fireside chat at the JMP Securities Hematology and Oncology Summit taking place virtually on December 5 – 6, 2023.

Notable Labs, Ltd. announced that the Company will present two posters related to its PPMP platform at the American Association for Cancer Research Annual Meeting 2024, taking place April 5-10, 2024 in San Diego, CA.

Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable” or the “Company”) today presented the design for the PPMP-enabled Phase 2 trial with volasertib, in combination with decitabine, in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) at the American Association for Cancer Research (AACR 2024) being held in San Diego, CA (Poster abstract 5178).

Notable Labs, Inc., a clinical stage therapeutic platform company developing predictive precision medicines for cancer patients, announced the completion of its merger transaction with VBL Therapeutics and associated financing.

Notable Labs, Ltd., a clinical-stage precision oncology company developing a new class of cancer therapies identified by its Predictive Precision Medicine Platform, presented data related to innovations in the use of cryopreserved samples in the PPMP assay at the American Association for Cancer Research being held in San Diego, CA.

Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable”, “Notable Labs”) today announced the advancement of its volasertib Phase 2 program utilizing PPMP to enrich the study population for clinical responders.

Notable Labs, Ltd. announced that it has filed its Quarterly Report on Form 10-Q containing financial results for the third quarter and nine months ended September 30, 2023.